Open in Screener

TLSI

TriSalus Life Sciences Inc

May 18 • 04:00PM ET

3.03

+0.35 13.06 %

Healthcare • Medical Devices • USA • Micro • NASD

May 14, 5:07 PMTriSalus cuts 2026 revenue outlook on salesforce disruption and TriNav Advance FDA delay

Peers: ANGO CLPT STXS NPCE IRMD

| Held by: VTI VXF IWM VTWO IWN IWC IWO VTWV RSSL VTWG

Index	RUT	P/E	-	EPS (ttm)	-1.41	Insider Own	32.54%	Shs Outstand	61.41M	Perf Week	-33.26%
Market Cap	186.10M	Forward P/E	-	EPS next Y	-0.16	Insider Trans	6.01%	Shs Float	41.43M	Perf Month	-34.84%
Enterprise Value	164.04M	PEG	-	EPS next Q	-0.15	Inst Own	33.78%	Short Float	3.48%	Perf Quarter	-36.48%
Income	-58.49M	P/S	4.15	EPS this Y	82.50%	Inst Trans	9.28%	Short Ratio	4.24	Perf Half Y	-30.98%
Sales	44.88M	P/B	14.53	EPS next Y	49.07%	ROA	-54.84%	Short Interest	1.44M	Perf YTD	-56.59%
Book/sh	0.21	P/C	3.29	EPS next 5Y	-	ROE	-	52W High	7.95 -61.89%	Perf Year	-41.05%
Cash/sh	0.92	P/FCF	-	EPS past 3/5Y	77.50% -140.62%	ROIC	-58.02%	52W Low	2.20 37.73%	Perf 3Y	-70.64%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	53.85% -	Gross Margin	85.07%	Volatility	24.12% 8.97%	Perf 5Y	-68.70%
Dividend TTM	-	EV/Sales	3.65	EPS Y/Y TTM	-25.99%	Oper. Margin	-62.45%	ATR (14)	0.37	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.46	Sales Y/Y TTM	39.64%	Profit Margin	-130.32%	RSI (14)	32.65	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.78	EPS Q/Q	107.57%	SMA20	-26.86%	Beta	0.51	Target Price	8.80
Payout	-	Debt/Eq	2.69	Sales Q/Q	-2.92%	SMA50	-26.88%	Rel Volume	2.27	Prev Close	2.68
Employees	102	LT Debt/Eq	2.68	Earnings	May 12 AMC	SMA200	-38.86%	Avg Volume	339.97K	Price	3.03
IPO	Feb 08, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	118.99% -12.67%	Trades		Volume	773,133	Change	13.06%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-13-25	Initiated	Lake Street	Buy
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$10
Nov-11-24	Initiated	ROTH MKM	Buy	$11
Oct-25-24	Initiated	Northland Capital	Outperform	$12.50
Sep-16-24	Initiated	Oppenheimer	Outperform	$10
May-30-24	Initiated	Canaccord Genuity	Buy	$12

May-14-26 01:03PM	Lost Money on TriSalus Life Sciences, Inc. (TLSI)? Contact Levi & Korsinsky to Protect Your Rights (Newsfile) -5.62%
May-13-26 01:01AM	TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ... (GuruFocus.com) -41.45%
May-12-26 08:47PM	TriSalus Life Sciences, Inc. Q1 2026 Earnings Call Summary (Moby)
04:01PM	TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth (Business Wire)
08:00AM	Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance (Business Wire)
09:21AM	Loading…
May-11-26 09:21AM	Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Reports Q1 2026 Result (GuruFocus.com)
May-04-26 05:24PM	TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors (Business Wire)
Apr-28-26 04:05PM	TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call (Business Wire) -5.12%
Apr-09-26 04:05PM	TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting (Business Wire)
Apr-07-26 09:15AM	TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer (Business Wire)
Mar-18-26 08:00AM	TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models (Business Wire)
Mar-06-26 08:30AM	TriSalus Life Sciences, Inc. Q4 2025 Earnings Call Summary (Moby) -6.39%
12:10AM	TriSalus Life Sciences Q4 Earnings Call Highlights (MarketBeat)
12:01AM	TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Mar-05-26 04:01PM	TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance (Business Wire)
07:22AM	Loading…
Mar-04-26 07:22AM	TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-25-26 04:05PM	TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call (Business Wire)
Feb-20-26 08:00AM	TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering (Business Wire) +18.22%
Feb-19-26 04:01PM	TriSalus Life Sciences Proposes Public Offering (Business Wire)
Feb-09-26 09:00AM	TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors (Business Wire)
Jan-14-26 12:00PM	TriSalus Life Sciences, Inc. (TLSI) Upgraded to Buy: Here's What You Should Know (Zacks)
Jan-12-26 07:00AM	TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance (Business Wire)
Dec-04-25 04:01PM	TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 (Business Wire) +5.37%
Nov-18-25 08:00AM	TriSalus Life Sciences Launches TriNav XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery (Business Wire)
Nov-14-25 12:04AM	TriSalus Life Sciences Inc (TLSI) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-13-25 05:15PM	TriSalus Life Sciences, Inc. (TLSI) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance (Business Wire)
Nov-12-25 07:29AM	TriSalus Life Sciences Inc (TLSI) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
07:10AM	Rockwell Medical (RMTI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-11-25 04:05PM	TriSalus Life Sciences to Participate in Upcoming Investor Conferences (Business Wire) +8.50%
08:00AM	Loading…
Nov-10-25 08:00AM	TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025 (Business Wire) -8.88%
Nov-06-25 07:00PM	ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Nov-05-25 06:15PM	biote Corp. (BTMD) Tops Q3 Earnings and Revenue Estimates (Zacks) -5.32%
Oct-30-25 08:00AM	TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call (Business Wire)
Aug-28-25 08:00AM	TriSalus Life Sciences to Participate in Upcoming September Investor Conferences (Business Wire)
Aug-13-25 03:12AM	TriSalus Life Sciences Inc (TLSI) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) +8.22%
Aug-12-25 05:10PM	TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance (Business Wire)
Aug-11-25 07:00PM	Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.62%
09:37AM	Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Reports Q2 2025 Result (GuruFocus.com)
08:00AM	TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique (Business Wire)
Aug-07-25 07:40AM	Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates (Zacks) -7.09%
Jul-30-25 04:05PM	TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Jul-29-25 04:05PM	TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call (Business Wire)
Jul-24-25 05:58PM	TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock (Business Wire)
Jun-23-25 05:30PM	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure (Business Wire) -5.37%
Jun-04-25 08:00AM	TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System (Business Wire)
May-30-25 07:00AM	TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience (Business Wire) -8.76%
May-16-25 03:01PM	TriSalus Life Sciences Inc (TLSI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
May-15-25 08:10AM	TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance (Business Wire)
May-12-25 07:15PM	OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised) (Zacks)
04:30PM	TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call (Business Wire)
07:45AM	OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
May-08-25 06:45PM	TerrAscend Corp. (TSNDF) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-30-25 08:15AM	SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -10.31%
08:00AM	TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results (Business Wire)
Apr-10-25 11:33AM	VAREX IMAGING (VREX) Moves 16.5% Higher: Will This Strength Last? (Zacks)
Apr-09-25 08:47AM	TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks)
Mar-30-25 08:02AM	TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks (Seeking Alpha)
Mar-27-25 02:02PM	TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:40AM	TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 08:00AM	TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav Infusion System Mapping (Business Wire)
Mar-06-25 08:00AM	TriSalus Life Sciences Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of "Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model" (Business Wire)
Feb-03-25 04:05PM	TriSalus Life Sciences Announces Key Appointments to Board of Directors (Business Wire)
08:00AM	TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed (Business Wire)
Jan-23-25 08:00AM	TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call (Business Wire) +5.31%
Jan-10-25 08:30AM	TriSalus Life Sciences announces publication of pre-clinical data (TipRanks) +7.95%
Jan-09-25 08:00AM	TriSalus Life Sciences Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres to Liver Tumors using Pressure-Enabled Drug Delivery (PEDD) via the TriNav Infusion System (Business Wire)
Jan-08-25 08:00AM	TriSalus Announces Leadership Changes (Business Wire) -7.18%
Nov-14-24 08:00AM	TriSalus Reports Q3 2024 Financial Results and Provides Business Update (Business Wire) -10.89%
Nov-13-24 07:27AM	TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-11-24 07:00AM	TriSalus Life Sciences Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav Infusion System to U.S. Veterans with Liver Cancer (Business Wire) +5.91%
Nov-07-24 07:00AM	TriSalus Life Sciences Launches TriNav LV Infusion System and TriGuide Guiding Catheters, Expanding Portfolio of PEDD Devices for Improved Tumor Treatment (Business Wire)
Oct-31-24 08:00AM	TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call (Business Wire)
Oct-14-24 04:05PM	TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit (Business Wire)
Sep-26-24 07:00AM	TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board (Business Wire)
Sep-23-24 07:00AM	TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD Method via the TriNav Infusion System (Business Wire) -6.70%
Sep-14-24 01:52AM	TriSalus Life Sciences Inc (TLSI) CEO Buys Shares (GuruFocus.com)
Aug-15-24 08:00AM	TriSalus Reports Q2 2024 Financial Results and Business Update (Business Wire)
Aug-01-24 07:00AM	TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call (Business Wire)
Jul-01-24 04:00PM	TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation (Business Wire) -5.07%
Jun-26-24 05:45PM	TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire)
Jun-03-24 07:00AM	TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting (Business Wire)
May-24-24 06:05AM	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire) -20.75%
May-15-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -7.49%
08:00AM	TriSalus Reports Q1 2024 Financial Results and Business Update (Business Wire)
May-07-24 07:00AM	TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors (Business Wire)
May-06-24 04:58PM	TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call (Business Wire)
Apr-30-24 04:35PM	TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav Infusion System Growth Initiatives (Business Wire)
Apr-01-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +5.13%
09:33AM	TriSalus Life Sciences Inc (TLSI) Q4 and Full Year 2023 Earnings: Revenue Growth Amidst Late ... (GuruFocus.com)
08:00AM	TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update (Business Wire)
Mar-26-24 08:00AM	TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting (Business Wire)
Mar-21-24 08:00AM	TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting (Business Wire)
Mar-11-24 05:15PM	TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results (Business Wire)
Mar-07-24 07:00AM	TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Associations Adopted Name Council for Nelitolimod as the Nonproprietary Drug Name for SD-101 (Business Wire)
Feb-29-24 07:00AM	TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors (Business Wire)
Dec-14-23 07:00AM	TriSalus Life Sciences Announces CMS Reimbursement for the TriNav Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code (Business Wire) +33.61%

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020 and is headquartered in Westminster, CO.

M.B.A.Ms. Mary T. Szela B.S.N.

Chief Financial OfficerMr. David B. Patience

VMDDr. Richard B. Marshak M.B.A.

Vice President of MarketingAndrea Marasso

Chief Regulatory OfficerMs. Jennifer L. Stevens J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wahlstrom Mats	Director	May 15 '26	Buy	2.53	60,000	151,800	147,555	May 18 04:42 PM
Stansky Michael P	Director	May 15 '26	Buy	2.50	410,000	1,025,000	1,240,722	May 18 04:42 PM
Stansky Michael P	Director	May 15 '26	Buy	2.50	200,000	500,000	399,698	May 18 04:42 PM
Szela Mary T	CEO and President	May 15 '26	Buy	2.59	39,682	102,776	1,065,215	May 18 04:42 PM
Patience David	Chief Financial Officer	May 15 '26	Buy	2.43	7,100	17,253	275,757	May 18 04:42 PM
Gordon Gary B.	Director	May 15 '26	Buy	2.46	10,000	24,600	72,510	May 18 04:42 PM
Devlin Jodi	Chief of Clinical Operations	Mar 12 '26	Sale	4.09	1,772	7,247	97,637	Mar 20 04:25 PM
Devlin Jodi	Chief of Clinical Operations	Mar 11 '26	Sale	4.13	1,162	4,799	99,409	Mar 20 04:25 PM
Devlin Jodi	Chief of Clinical Operations	Mar 16 '26	Sale	4.12	273	1,125	97,364	Mar 20 04:25 PM
Cox Bryan F.	Chief of Research	Mar 12 '26	Sale	4.09	1,467	6,000	163,994	Mar 20 04:25 PM
Cox Bryan F.	Chief of Research	Mar 11 '26	Sale	4.13	1,138	4,700	165,461	Mar 20 04:25 PM
Cox Bryan F.	Chief of Research	Mar 16 '26	Sale	4.12	579	2,385	163,415	Mar 20 04:25 PM
Marshak Richard	Chief Commercial Officer	Mar 12 '26	Sale	4.09	1,589	6,499	110,816	Mar 20 04:25 PM
Marshak Richard	Chief Commercial Officer	Mar 11 '26	Sale	4.13	1,449	5,984	112,405	Mar 20 04:25 PM
Marshak Richard	Chief Commercial Officer	Mar 16 '26	Sale	4.12	419	1,726	110,397	Mar 20 04:25 PM
Stevens Jennifer	Chief Regulatory Officer	Mar 12 '26	Sale	4.09	1,552	6,348	124,884	Mar 20 04:25 PM
Stevens Jennifer	Chief Regulatory Officer	Mar 11 '26	Sale	4.13	1,204	4,973	126,436	Mar 20 04:25 PM
Stevens Jennifer	Chief Regulatory Officer	Mar 16 '26	Sale	4.12	774	3,189	124,110	Mar 20 04:25 PM
Szela Mary T	CEO and President	Mar 17 '26	Sale	3.85	15,944	61,384	752,987	Mar 20 04:25 PM
Szela Mary T	CEO and President	Mar 11 '26	Sale	4.13	4,358	17,999	768,931	Mar 20 04:25 PM
Patience David	Chief Financial Officer	Feb 23 '26	Buy	4.10	3,657	14,994	268,657	Feb 23 04:08 PM
Gordon Gary B.	Director	Feb 23 '26	Buy	4.10	9,756	40,000	9,756	Feb 23 04:08 PM
Valle William	Director	Feb 23 '26	Buy	4.10	30,487	124,997	30,487	Feb 23 04:08 PM
Szela Mary T	CEO and President	Feb 23 '26	Buy	4.10	30,487	124,997	773,289	Feb 23 04:08 PM
Stansky Michael P	Director	Feb 23 '26	Buy	4.10	243,900	999,990	787,132	Feb 23 04:08 PM
Stansky Michael P	Director	Feb 23 '26	Buy	4.10	117,198	480,512	199,698	Feb 23 04:08 PM
Cox Bryan F.	Chief of Research	May 19 '25	Sale	5.18	4,764	24,678	119,415	May 21 05:33 PM
Devlin Jodi	Chief of Clinical Operations	May 19 '25	Sale	5.18	4,764	24,678	52,764	May 21 05:31 PM
Marshak Richard	Chief Commercial Officer	May 19 '25	Sale	5.18	6,597	34,172	69,101	May 21 05:30 PM
Stevens Jennifer	Chief Regulatory Officer	May 19 '25	Sale	5.18	8,704	45,087	77,640	May 21 05:27 PM

Open in Screener

CHRS

Coherus Oncology Inc

May 18 • 04:00PM ET

1.49

-0.08 -5.10 %

Healthcare • Biotechnology • USA • Micro • NASD

CHRS Coherus Oncology Inc daily Stock Chart

Peers: STRO ADCT BDTX KURA CRBP

| Held by: VTI IWM VXF SCHA IWN VTWO IWO IWC PRFZ SCHB

Index	RUT	P/E	-	EPS (ttm)	-1.25	Insider Own	22.49%	Shs Outstand	154.22M	Perf Week	-23.59%
Market Cap	229.83M	Forward P/E	-	EPS next Y	-0.64	Insider Trans	0.00%	Shs Float	119.56M	Perf Month	-24.75%
Enterprise Value	117.15M	PEG	-	EPS next Q	-0.24	Inst Own	35.35%	Short Float	23.27%	Perf Quarter	-7.45%
Income	-151.66M	P/S	4.90	EPS this Y	34.94%	Inst Trans	-3.88%	Short Ratio	20.88	Perf Half Y	18.25%
Sales	46.88M	P/B	2.92	EPS next Y	37.14%	ROA	-54.20%	Short Interest	27.82M	Perf YTD	4.93%
Book/sh	0.51	P/C	1.38	EPS next 5Y	32.26%	ROE	-860.65%	52W High	2.62 -43.04%	Perf Year	95.80%
Cash/sh	1.08	P/FCF	-	EPS past 3/5Y	27.14% -	ROIC	-115.69%	52W Low	0.71 109.86%	Perf 3Y	-66.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-41.54% -38.41%	Gross Margin	60.04%	Volatility	9.27% 6.55%	Perf 5Y	-89.23%
Dividend TTM	-	EV/Sales	2.50	EPS Y/Y TTM	-9.93%	Oper. Margin	-362.07%	ATR (14)	0.13	Perf 10Y	-92.36%
Dividend Ex-Date	-	Quick Ratio	1.52	Sales Y/Y TTM	-76.26%	Profit Margin	-323.49%	RSI (14)	36.30	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	1.56	EPS Q/Q	43.03%	SMA20	-14.59%	Beta	1.00	Target Price	7.80
Payout	-	Debt/Eq	0.69	Sales Q/Q	61.99%	SMA50	-14.09%	Rel Volume	1.33	Prev Close	1.57
Employees	147	LT Debt/Eq	0.67	Earnings	May 11 AMC	SMA200	-4.15%	Avg Volume	1.33M	Price	1.49
IPO	Nov 06, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.54% -13.42%	Trades		Volume	1,770,219	Change	-5.10%

Date	Action	Analyst	Rating Change	Price Target Change
May-11-26	Initiated	Guggenheim	Buy	$12
Jan-23-26	Initiated	Oppenheimer	Outperform	$10
Sep-04-25	Upgrade	Maxim Group	Hold → Buy
Aug-16-24	Downgrade	UBS	Buy → Neutral	$4 → $1.50
Nov-17-23	Initiated	Robert W. Baird	Outperform	$11
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy	$12
May-01-23	Initiated	Truist	Buy	$24
Mar-28-23	Upgrade	UBS	Neutral → Buy	$11
Jun-14-22	Initiated	UBS	Neutral	$7
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral	$15
Jul-16-20	Initiated	BofA Securities	Neutral	$20
Apr-17-20	Initiated	SunTrust	Buy	$26
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	Maxim Group	Buy	$25 → $27
Aug-02-19	Reiterated	H.C. Wainwright	Buy	$28 → $29
Jun-11-19	Initiated	Barclays	Overweight	$30
May-07-19	Initiated	H.C. Wainwright	Buy	$28
Aug-28-18	Initiated	H.C. Wainwright	Buy	$28
Mar-09-18	Reiterated	Maxim Group	Buy	$20 → $15

Show Previous Ratings

May-12-26 08:30AM	Coherus Oncology, Inc. Q1 2026 Earnings Call Summary (Moby) -12.31%
03:07AM	Coherus Oncology Inc (CHRS) Q1 2026 Earnings Call Highlights: Strong LOQTORZI Sales Growth Amid ... (GuruFocus.com)
May-11-26 04:23PM	Coherus Oncology: Q1 Earnings Snapshot (Associated Press) +11.43%
04:05PM	Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-04-26 09:30AM	Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 (GlobeNewswire)
11:01PM	Loading…
Mar-09-26 11:01PM	Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +6.04%
05:35PM	Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:38PM	Coherus Oncology: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-08-26 05:27AM	Coherus Oncology Touts 90% Debt Cut, LOQTORZI Sales Surge, Sets 2026 Data Catalysts (MarketBeat)
Mar-02-26 09:30AM	Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 (GlobeNewswire)
Feb-26-26 12:15PM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-24-26 09:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates (Zacks)
Feb-23-26 07:25PM	Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates (Zacks)
09:30AM	Coherus Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:11PM	Loading…
Feb-17-26 04:11PM	Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock (GlobeNewswire)
Feb-12-26 09:18PM	Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -19.90%
05:20PM	Vertex Pharmaceuticals (VRTX) Q4 Earnings Miss Estimates (Zacks)
04:05PM	Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-27-26 10:50AM	Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks (PR Newswire) +10.09%
Jan-16-26 08:00AM	Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape (PR Newswire)
Jan-14-26 06:14AM	Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains? (Zacks) -5.88%
Jan-06-26 09:30AM	Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.56%
Jan-05-26 09:30AM	Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) (GlobeNewswire) +5.11%
Dec-08-25 08:30AM	Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma (GlobeNewswire) +6.67%
Nov-07-25 09:00AM	Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody (GlobeNewswire) -10.07%
12:09AM	Coherus Oncology Inc (CHRS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-25 08:15PM	Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:10PM	Coherus Oncology: Q3 Earnings Snapshot (Associated Press Finance)
04:14PM	Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
01:54PM	Loading…
01:54PM	Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer (GlobeNewswire)
Oct-30-25 05:35PM	Illumina (ILMN) Beats Q3 Earnings and Revenue Estimates (Zacks)
08:30AM	Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-23-25 08:30AM	Coherus Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-03-25 09:05AM	Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Sep-03-25 08:30AM	Coherus Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.88%
Aug-08-25 08:18AM	Intas Pharmaceuticals acquires Udenyca from Coherus BioSciences (Pharmaceutical Business Review) -7.13%
03:40AM	Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Aug-07-25 06:25PM	Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
05:30PM	Coherus Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:41PM	Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-06-25 06:10PM	Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 (Zacks)
10:29AM	Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA® (PR Newswire)
Jul-31-25 04:45PM	Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire) -6.64%
Jun-25-25 09:55AM	Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? (Zacks) -6.08%
Jun-06-25 04:29PM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey)
May-30-25 08:00AM	Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics (GlobeNewswire)
May-27-25 08:30AM	Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI (toripalimab-tpzi) (GlobeNewswire)
May-13-25 02:22PM	Q1 2025 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) -19.11%
03:10AM	Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... (GuruFocus.com)
May-12-25 05:30PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.30%
04:27PM	Coherus BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 09:45AM	What To Expect From Coherus BioSciences Inc (CHRS) Q1 2025 Earnings (GuruFocus.com)
May-05-25 04:01PM	Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire) -7.27% -8.83%
May-01-25 05:04PM	Coherus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-28-25 10:10AM	Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 (GlobeNewswire)
Apr-17-25 05:53AM	Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs (Seeking Alpha) +10.89%
Apr-15-25 09:44AM	Coherus divests Udenyca franchise to Intas for up to $558.4m (Pharmaceutical Technology) +8.76%
Apr-14-25 08:00AM	Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA Franchise (GlobeNewswire) +16.59%
Apr-01-25 08:00AM	Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes (GlobeNewswire)
Mar-25-25 04:30PM	Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -5.81%
Mar-21-25 07:10AM	Lazard Enhanced Opportunities Portfolio Q4 2024 Commentary (SeekingAlpha) +8.83%
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 03:23PM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey) -6.67%
Mar-11-25 01:46PM	Q4 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Mar-10-25 04:32PM	Coherus BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
04:12PM	Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-25 07:06AM	What To Expect From Coherus BioSciences Inc (CHRS) Q4 2024 Earnings (GuruFocus.com)
Mar-03-25 08:30AM	Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 (GlobeNewswire) -9.46%
Feb-24-25 09:08AM	Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire) +7.48%
Feb-12-25 08:39AM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey)
Jan-22-25 07:00AM	Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 (GlobeNewswire)
Jan-08-25 08:00AM	Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 08:30AM	Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 (GlobeNewswire) -8.19%
Dec-03-24 07:00AM	Coherus Announces Agreement to Divest UDENYCA Franchise for up to $558 million to Intas Pharmaceuticals Ltd. (GlobeNewswire) +24.82%
06:06AM	Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M (BioPharma Dive)
Nov-27-24 04:01PM	Coherus Management to Participate in the 2024 Citi Global Healthcare Conference (GlobeNewswire)
Nov-07-24 01:09PM	Q3 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) +13.29%
02:26AM	Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-06-24 05:15PM	Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Coherus BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:08AM	Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +9.10%
Oct-30-24 04:20PM	Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-09-24 06:01PM	Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Sep-28-24 07:24AM	Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:28AM	Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges (Insider Monkey)
Aug-08-24 05:50PM	Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.85%
04:45PM	Coherus BioSciences: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 09:00AM	Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire) -7.14%
Jun-28-24 07:49AM	PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar (BioPharma Dive)
Jun-27-24 08:26AM	Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction (GlobeNewswire)
Jun-05-24 09:00AM	Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors (GlobeNewswire)
May-30-24 09:00AM	Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 05:51PM	Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
09:00AM	Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA (GlobeNewswire)
May-13-24 09:23AM	Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating (MT Newswires) +10.00%

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

ChairmanMr. Dennis M. Lanfear

Chief Financial OfficerMr. Bryan J. McMichael

Vice President of Investor Relations & AdvocacyMs. Carrie Graham

Chief Legal OfficerMr. Andy Rittenberg

Chief Human Resources OfficerMs. Rebecca Sunshine

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wahlstrom Mats	Director	May 23 '25	Sale	0.74	99,988	73,881	0	May 28 05:12 PM

TLSI

TriSalus Life Sciences Inc

CHRS

Coherus Oncology Inc

Upgrade your Finviz experience